ECSP099571A - Derivados pirazólicos como inhibidores de la 11-beta-hsd1 - Google Patents

Derivados pirazólicos como inhibidores de la 11-beta-hsd1

Info

Publication number
ECSP099571A
ECSP099571A EC2009009571A ECSP099571A ECSP099571A EC SP099571 A ECSP099571 A EC SP099571A EC 2009009571 A EC2009009571 A EC 2009009571A EC SP099571 A ECSP099571 A EC SP099571A EC SP099571 A ECSP099571 A EC SP099571A
Authority
EC
Ecuador
Prior art keywords
pirazolic
hsd1
inhibitors
beta
derivatives
Prior art date
Application number
EC2009009571A
Other languages
English (en)
Inventor
Martin Packer
James Stewart Scott
Paul Robert Owen Whittamore
Andrew Stocker
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39438215&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ECSP099571(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of ECSP099571A publication Critical patent/ECSP099571A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D231/18—One oxygen or sulfur atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/46—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of glucocorticosteroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
    • A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
    • C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D231/14—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Diabetes (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Child & Adolescent Psychology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Un compuesto de la fórmula (I): y sales farmacéuticamente aceptables de este donde los grupos variables se definen en la presente; y también se describe su uso en la inhibición de la 11ßHSD1, procesos para prepararlos y composiciones farmacéuticas que los comprenden.
EC2009009571A 2007-02-12 2009-08-11 Derivados pirazólicos como inhibidores de la 11-beta-hsd1 ECSP099571A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US88933607P 2007-02-12 2007-02-12
US98573507P 2007-11-06 2007-11-06

Publications (1)

Publication Number Publication Date
ECSP099571A true ECSP099571A (es) 2009-09-29

Family

ID=39438215

Family Applications (1)

Application Number Title Priority Date Filing Date
EC2009009571A ECSP099571A (es) 2007-02-12 2009-08-11 Derivados pirazólicos como inhibidores de la 11-beta-hsd1

Country Status (23)

Country Link
US (2) US7816391B2 (es)
EP (2) EP2124937A1 (es)
JP (1) JP2010518063A (es)
KR (1) KR20090108726A (es)
CN (1) CN102503891A (es)
AR (1) AR065300A1 (es)
AU (1) AU2008215976B2 (es)
BR (1) BRPI0808450A2 (es)
CA (1) CA2676154A1 (es)
CL (1) CL2008000422A1 (es)
CO (1) CO6220949A2 (es)
EC (1) ECSP099571A (es)
IL (1) IL200047A0 (es)
MX (1) MX2009008506A (es)
NZ (1) NZ578568A (es)
PE (2) PE20120355A1 (es)
RU (2) RU2462456C2 (es)
SA (1) SA08290055B1 (es)
SG (1) SG177892A1 (es)
TW (1) TW200836719A (es)
UY (1) UY30912A1 (es)
WO (1) WO2008099145A1 (es)
ZA (1) ZA201000838B (es)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102659659B (zh) 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
AU2008252185B2 (en) 2007-05-18 2012-02-16 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type I inhibitory activity
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
WO2009098501A1 (en) * 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
MX2010011591A (es) * 2008-04-22 2010-11-09 Astrazeneca Ab Pirimidin-5-carboxamidas sustituidas 281.
US20120041211A1 (en) * 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
US8507493B2 (en) 2009-04-20 2013-08-13 Abbvie Inc. Amide and amidine derivatives and uses thereof
WO2011068927A2 (en) * 2009-12-04 2011-06-09 Abbott Laboratories 11-β-HYDROXYSTEROID DEHYDROGENASE TYPE 1 (11B-HSD1) INHIBITORS AND USES THEREOF
WO2011107494A1 (de) 2010-03-03 2011-09-09 Sanofi Neue aromatische glykosidderivate, diese verbindungen enthaltende arzneimittel und deren verwendung
GB201004301D0 (en) * 2010-03-15 2010-04-28 Syngenta Participations Ag Process
EP2582709B1 (de) 2010-06-18 2018-01-24 Sanofi Azolopyridin-3-on-derivate als inhibitoren von lipasen und phospholipasen
US8530413B2 (en) 2010-06-21 2013-09-10 Sanofi Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
TW201221505A (en) 2010-07-05 2012-06-01 Sanofi Sa Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
TW201215388A (en) 2010-07-05 2012-04-16 Sanofi Sa (2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
TW201215387A (en) 2010-07-05 2012-04-16 Sanofi Aventis Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
JP5605104B2 (ja) * 2010-09-10 2014-10-15 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2012176717A1 (ja) 2011-06-22 2012-12-27 セントラル硝子株式会社 ピラゾール化合物の製造方法
JP5915004B2 (ja) * 2011-06-22 2016-05-11 セントラル硝子株式会社 ピラゾール化合物の製造方法
WO2013037390A1 (en) 2011-09-12 2013-03-21 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
EP2760862B1 (en) 2011-09-27 2015-10-21 Sanofi 6-(4-hydroxy-phenyl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
JP2015129094A (ja) * 2012-04-16 2015-07-16 大日本住友製薬株式会社 アリールアミノピラゾール誘導体
WO2019042267A1 (zh) * 2017-08-28 2019-03-07 中国医学科学院药物研究所 吡咯-2-甲酰胺类化合物及其制备方法和用途

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GR66581B (es) 1978-02-21 1981-03-27 Delalande Sa
US4816391A (en) * 1984-02-29 1989-03-28 Syntex (U.S.A.) Inc. Amine stabilized aminoglycoside formulations
US4734418A (en) 1984-12-14 1988-03-29 Mitsui Petrochemical Industries, Ltd. Quinazoline compounds and antihypertensives
CA2383466C (en) 1999-09-16 2009-08-25 Tanabe Seiyaku Co., Ltd. Aromatic nitrogen-containing 6-membered cyclic compounds
US7273868B2 (en) 2000-04-28 2007-09-25 Tanabe Seiyaku Co., Ltd. Pyrazine derivatives
US6777446B2 (en) 2000-09-05 2004-08-17 Tularik, Inc. FXR modulators
CA2426430C (en) 2000-10-20 2014-10-07 Biocryst Pharmaceuticals, Inc. Biaryl compounds as serine protease inhibitors
SE0102764D0 (sv) 2001-08-17 2001-08-17 Astrazeneca Ab Compounds
JP2005528395A (ja) 2002-04-05 2005-09-22 ザ ユニバーシティ オブ エディンバラ 組成物
TW200503994A (en) 2003-01-24 2005-02-01 Novartis Ag Organic compounds
WO2004076420A1 (ja) 2003-02-26 2004-09-10 Banyu Pharmaceutical Co., Ltd. ヘテロアリールカルバモイルベンゼン誘導体
DE602004027171D1 (de) 2003-04-11 2010-06-24 High Point Pharmaceuticals Llc Verbindungen mit Aktivität an der 11Beta-Hydroxasteroiddehydrogenase
EP1653949A4 (en) 2003-08-07 2009-04-22 Merck & Co Inc PYRAZOL CARBOXAMIDE AS AN INHIBITOR OF 11-BETA-HYDROXYSTEROID DEHYDROGENASE-1
SG146624A1 (en) 2003-09-11 2008-10-30 Kemia Inc Cytokine inhibitors
GB0327761D0 (en) 2003-11-29 2003-12-31 Astrazeneca Ab Compounds
BRPI0417687A (pt) 2003-12-19 2007-04-03 Pfizer derivados de benzenossulfonilamino-piridin-2-ila e compostos relacionados como inibidores de 11-beta-hidroxiesteróide desidrogenase tipo 1 (11-beta-hsd-1) para o tratamento de diabetes e obesidade
WO2005108359A1 (en) 2004-05-06 2005-11-17 Pfizer Inc. Novel compounds of proline and morpholine derivatives
TW200600086A (en) 2004-06-05 2006-01-01 Astrazeneca Ab Chemical compound
ATE509011T1 (de) 2004-06-28 2011-05-15 Hoffmann La Roche Pyrimidinderivate als 11beta-hsd1-inhibitoren
EP1812407A2 (en) 2004-11-02 2007-08-01 Pfizer, Inc. Novel compounds of substituted and unsubstituted adamantyl amides
EP1809290A2 (en) 2004-11-03 2007-07-25 Vertex Pharmaceuticals Incorporated Pyrimidine derivatives as ion channel modulators and methods of use
KR101496190B1 (ko) 2005-01-05 2015-02-26 애브비 인코포레이티드 11-베타-하이드록시스테로이드 데하이드로게나제 타입 1 효소의 억제제로서의 아다만틸 유도체
WO2006106052A1 (en) 2005-04-05 2006-10-12 F. Hoffmann-La Roche Ag Pyrazoles
ES2326280T3 (es) 2005-04-06 2009-10-06 F. Hoffmann-La Roche Ag Derivados de piridin-3-carboxamida como agonistas inversos de cb1.
WO2006106423A2 (en) 2005-04-07 2006-10-12 Pfizer Inc. Amino sulfonyl derivatives as inhibitors of human 11-.beta.-hydrosysteroid dehydrogenase
EP1879881A2 (en) 2005-04-14 2008-01-23 Bristol-Myers Squibb Company Inhibitors of 11-beta hydroxysteroid dehydrogenase type i
EP1891069A1 (en) 2005-05-24 2008-02-27 AstraZeneca AB 2-phenyl substituted imidazol [4,5b]pyridine/ pyrazine and purine derivatives as glucokinase modulators
TW200716576A (en) 2005-06-07 2007-05-01 Shionogi & Co Heterocyclic derivatives as inhibitors of 11-beta-hydroxysteroid dehydrogenase 1
KR100970294B1 (ko) * 2005-06-08 2010-07-15 니뽄 다바코 산교 가부시키가이샤 복소환 화합물
KR20080016649A (ko) 2005-06-16 2008-02-21 화이자 인코포레이티드 Ｎ-(피리딘-2-일)-술폰아미드 유도체
KR20110084339A (ko) 2005-07-09 2011-07-21 아스트라제네카 아베 당뇨병 치료에 있어 ｇｌｋ 활성화제로서 사용하기 위한 헤테로아릴 벤즈아미드 유도체
WO2007017649A1 (en) 2005-08-09 2007-02-15 Astrazeneca Ab Heteroarylcarbamoylbenzene derivatives for the treatment of diabetes
CA2627813A1 (en) 2005-11-01 2007-05-10 Janssen Pharmaceutica N.V. Substituted pyrrolones as allosteric modulators of glucokinase
WO2007052843A1 (ja) 2005-11-04 2007-05-10 Takeda Pharmaceutical Company Limited 複素環アミド化合物およびその用途
CN102659659B (zh) * 2005-11-21 2014-07-23 盐野义制药株式会社 具有I型11β羟基类固醇脱氢酶抑制活性的杂环化合物
BRPI0707408A2 (pt) 2006-01-31 2011-05-03 Incyte Corp compostos de amido e seu uso como produtos farmacêuticos
CN101405270B (zh) * 2006-03-22 2013-01-16 霍夫曼-拉罗奇有限公司 作为11-β-HSD-1的吡唑类
EP2010479A1 (en) 2006-04-07 2009-01-07 High Point Pharmaceuticals, LLC 11 beta-hydroxysteroid dehydrogenase type 1 active compounds
WO2007125049A1 (en) 2006-04-27 2007-11-08 Solvay Pharmaceuticals Gmbh Use of cbx cannabinoid receptor modulators as potassium channel modulators
WO2008012532A2 (en) 2006-07-27 2008-01-31 Astrazeneca Ab : pyridine-3-carboxamide compounds and their use for inhibiting 11-beta-hydroxysteroid dehydrogenase
TW200827346A (en) 2006-11-03 2008-07-01 Astrazeneca Ab Chemical compounds
TW200836719A (en) 2007-02-12 2008-09-16 Astrazeneca Ab Chemical compounds
AU2008252185B2 (en) 2007-05-18 2012-02-16 Shionogi & Co., Ltd. Nitrogen-containing heterocyclic derivative having 11 beta-hydroxysteroid dehydrogenase type I inhibitory activity
AU2008277783B2 (en) 2007-07-17 2012-09-20 F. Hoffmann-La Roche Ag Inhibitors of 11beta-hydroxysteroid dehydrogenase
EA201000701A1 (ru) * 2007-11-06 2010-12-30 Астразенека Аб 4-[4-(2-адамантилкарбамоил)-5-трет-бутилпиразол-1-ил]бензойная кислота-465
WO2009098501A1 (en) 2008-02-04 2009-08-13 Astrazeneca Ab Novel crystalline forms of 4- [4- (2-adamantylcarbam0yl) -5-tert-butyl-pyrazol-1-yl] benzoic acid
MX2010011591A (es) 2008-04-22 2010-11-09 Astrazeneca Ab Pirimidin-5-carboxamidas sustituidas 281.
US20120041211A1 (en) 2009-01-30 2012-02-16 Sythana Suresh Kumar Novel process for preparing carboxy-containing pyrazoleamido compounds 597
TW201118085A (en) * 2009-10-20 2011-06-01 Astrazeneca Ab Adamantyl iminocarbonyl-substituted pyrimidines as inhibitors of 11-β-HSD1

Also Published As

Publication number Publication date
AU2008215976A1 (en) 2008-08-21
CA2676154A1 (en) 2008-08-21
EP2124937A1 (en) 2009-12-02
BRPI0808450A2 (pt) 2014-08-12
CL2008000422A1 (es) 2009-01-02
NZ578568A (en) 2012-01-12
TW200836719A (en) 2008-09-16
SG177892A1 (en) 2012-02-28
AU2008215976B2 (en) 2011-11-24
RU2462456C2 (ru) 2012-09-27
CN102503891A (zh) 2012-06-20
PE20120355A1 (es) 2012-05-17
JP2010518063A (ja) 2010-05-27
UY30912A1 (es) 2008-09-30
MX2009008506A (es) 2009-10-12
CO6220949A2 (es) 2010-11-19
KR20090108726A (ko) 2009-10-16
ZA201000838B (en) 2010-10-27
IL200047A0 (en) 2010-04-15
US8344016B2 (en) 2013-01-01
PE20090649A1 (es) 2009-06-26
RU2012125372A (ru) 2013-12-27
AR065300A1 (es) 2009-05-27
WO2008099145A1 (en) 2008-08-21
US20090221663A1 (en) 2009-09-03
RU2009133259A (ru) 2011-03-20
EP2292228A1 (en) 2011-03-09
US20110224273A1 (en) 2011-09-15
US7816391B2 (en) 2010-10-19
SA08290055B1 (ar) 2012-09-26

Similar Documents

Publication Publication Date Title
CO6321254A2 (es) Pirimidin -5-carboxamidas sustituidas 281
UY30912A1 (es) Derivados de 4-pirazol amidas conteniendo carboxi, sales farmacéuticamente aceptables de los mismo, composiciones farmacéuticas conteniéndolos, procesos de preparacion y uso.
UY31069A1 (es) Nuevos derivados de imidazoquinola, composiciones conteniendolos, proceso de preparacion y aplicaciones
CR11518A (es) Compuestos de carbamoilo como inhibidores de dgat1 190
PA8791801A1 (es) Compuestos de pirazol
ECSP109856A (es) Derivados de oxadiazol y su uso como potenciadores de los receptores metabotrópicos de glutamato - 842
DOP2010000183A (es) Derivados de itazol usados como inhibidores de pi 3-cinasa
CR20120283A (es) Inhibidor de bromodominio de benzodiazepina
UY30444A1 (es) Derivados de pirimidina, procesos para su preparacinn, composiciones farmaccuticos y usos de los mismos.
ECSP099721A (es) Inhibidores de cinasa p70 s6
ECSP10010272A (es) Derivados bis-(sulfonilamino) para uso en terapia
UY31906A (es) Derivados de n-cicloalquil-3-fenilnicotinamida que inhiben pgds, sus composiciones, su uso para el tratamiento por ejemplo de afecciones alérgicas y respiratorias.
CO6290656A2 (es) Derivados heterociclicos de urea y metodos de uso de los mismos -211
UY32158A (es) Derivados heterociclicos y metodos de uso de los mismos
UY31639A1 (es) Derivados de amida espirocíclica de fórmula i, sales farmacéuticamente aceptables, composiciones farmacéuticas conteniéndolas, procesos de preparación y aplicaciones
DOP2009000200A (es) Derivados de 2-amino-5,7-dihidro-6h-pirrolo[3,4-d] pimiridina como inhibidores hsp-90 para tratar el cancer
ECSP088700A (es) Acidos 4-fenil-tiazol-5-carboxilicos y amidas de acidos 4-fenil-tiazol-5-carboxilicos como inhibidores de la plk1
UY31905A (es) Derivados de benzoxazinona, procesos de preparación, composiciones farmacéuticas conteniéndolos y aplicaciones.
SV2010003752A (es) Derivados de urea heterociclicos para el tratamiento de infecciones bacterianas
UY32954A (es) PIRIMIDINAS SUSTITUIDAS CON ADAMANTILIMINOCARBONILO COMO INHIBIDORES DE 11-ß-HSD1 826?.
UY32674A (es) Derivados heterociclicos de la urea y sus metodos de empleo
DOP2010000155A (es) Derivados de pirazol como inhibidores de 5-lo
UY32316A (es) Derivados de piperidina utiles en el tratamiento de infecciones bacterianas
UY30417A1 (es) Derivados de aril y heteroaril-etil-acilguanidina,su preparacion y su aplicacion en terapeutica
ECSP13012372A (es) Nuevos derivados 1,4-diazepanos, inhibidores de pde-5.